Skye Bioscience Announced Non-Exclusive License Agreement For Halozyme Therapeutics' Enhanze Drug Delivery Technology For The Development And Potential Commercialization Of A Subcutaneous Formulation Of Nimacimab For Obesity

Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE for at least 10 years.

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.